Zai Lab Limited (NASDAQ:ZLAB) Director William Lis Sells 10,397 Shares

Zai Lab Limited (NASDAQ:ZLAB) Director William Lis sold 10,397 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $17.32, for a total transaction of $180,076.04. Following the transaction, the director now directly owns 53,089 shares in the company, valued at $919,501.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Zai Lab Stock Down 0.9 %

ZLAB stock traded down $0.15 during trading on Wednesday, hitting $17.22. 192,017 shares of the company’s stock traded hands, compared to its average volume of 630,227. The firm has a market capitalization of $1.71 billion, a P/E ratio of -4.98 and a beta of 1.06. The business has a fifty day simple moving average of $18.45 and a two-hundred day simple moving average of $19.89. Zai Lab Limited has a 1 year low of $13.48 and a 1 year high of $32.60.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.38. Zai Lab had a negative net margin of 116.45% and a negative return on equity of 40.21%. The business had revenue of $87.15 million for the quarter, compared to analyst estimates of $77.07 million. During the same period in the previous year, the company earned ($0.51) earnings per share. On average, equities research analysts predict that Zai Lab Limited will post -2.78 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a report on Monday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $64.57.

Hedge Funds Weigh In On Zai Lab

Institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP lifted its stake in shares of Zai Lab by 177.6% during the fourth quarter. Wellington Management Group LLP now owns 5,336,457 shares of the company’s stock worth $145,845,000 after buying an additional 3,413,829 shares during the period. Capital World Investors lifted its stake in shares of Zai Lab by 8.9% during the first quarter. Capital World Investors now owns 5,684,180 shares of the company’s stock worth $91,061,000 after buying an additional 465,337 shares during the period. M&G Plc acquired a new position in Zai Lab during the first quarter valued at $7,266,000. Janus Henderson Group PLC lifted its position in Zai Lab by 9.6% during the first quarter. Janus Henderson Group PLC now owns 4,428,011 shares of the company’s stock valued at $70,924,000 after purchasing an additional 387,729 shares during the period. Finally, Brilliance Asset Management Ltd. lifted its position in Zai Lab by 177.5% during the fourth quarter. Brilliance Asset Management Ltd. now owns 435,926 shares of the company’s stock valued at $11,914,000 after purchasing an additional 278,841 shares during the period. 41.65% of the stock is owned by hedge funds and other institutional investors.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.